NASDAQ · CUE
Cue Biopharma, Inc.
$21.45+$0.29 (+1.37%)
Cue Biopharma, Inc.’s quoted price sits in the lower half of its reported 52-week range, 52.86% below the high.
Loading market information…
NASDAQ · SPRB · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Spruce Biosciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 63.71% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Spruce Biosciences, Inc.’s next earnings report is currently expected on Nov 9, 2026, with estimated earnings per share of -$5.68. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Spruce Biosciences, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Spruce Biosciences, Inc., founded in 2014 and situated in Daly City, California, operates as a biopharmaceutical enterprise. Its primary objective is to advance and bring to market innovative treatments, particularly for uncommon endocrine conditions. A central component of its therapeutic pipeline is tildacerfont, a non-steroidal drug candidate. This compound is currently undergoing Phase 2b clinical assessments in adult patients with congenital adrenal hyperplasia (CAH), with the aim of optimizing disease management and lessening dependence on steroid medications by examining reductions in glucocorticoid levels and their clinical consequences. Tildacerfont is also progressing through Phase 2 trials for pediatric classic CAH, as well as investigating its efficacy in women suffering from polycystic ovary syndrome (PCOS). Additionally, Spruce Biosciences maintains a collaborative licensing agreement with Eli Lilly and Company to jointly explore, formulate, and commercialize various pharmaceutical substances.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 01:39 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| -$24.00-27.66% vs estimate |
| $0.00-100.0% vs estimate |
| Q1 2025 | Apr 15, 2025 | -$42.75-17,712.05% vs estimate | $700.00K-20.9% vs estimate |
|---|
| Q3 2024 | Nov 11, 2024 | -$15.79-5,748.15% vs estimate | $602.00K-59.7% vs estimate |
|---|
THE ANALYST VIEW
11 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 4 contributors · Median target $149.50.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$21.45+$0.29 (+1.37%)
Cue Biopharma, Inc.’s quoted price sits in the lower half of its reported 52-week range, 52.86% below the high.
$0.49-$0.05 (-9.43%)
Outlook Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 80.57% below the high.
$2.66-$0.03 (-1.12%)
NRx Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 47.43% below the high.
$26.38+$0.66 (+2.57%)
vTv Therapeutics Inc.’s quoted price sits in the lower half of its reported 52-week range, 40.05% below the high.
$1.42$0.00 (0.0%)
Equillium, Inc.’s quoted price sits in the lower half of its reported 52-week range, 59.89% below the high.
$1.30+$0.05 (+4.0%)
OS Therapies Incorporated’s quoted price sits in the lower half of its reported 52-week range, 42.22% below the high.
$1.10+$0.04 (+3.77%)
Werewolf Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 53.78% below the high.
$10.99-$1.03 (-8.57%)
Coeptis Therapeutics Holdings, Inc.’s quoted price sits in the lower half of its reported 52-week range, 48.67% below the high.
